News
Announcing better-than-expected financials for Q1 2025, Merck (NYSE:MRK) lowered its full-year outlook for earnings to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback